Anti-SARS-CoV-2 and SARS-CoV nucleocapsid [mBG17]

Absolute Antibody

Anti-SARS-CoV-2 and SARS-CoV nucleocapsid [mBG17]

9

mBG17 strongly recognizes SARS-CoV-2 N protein and SARS-CoV N protein. To lesser extent, it cross-reacts with the HuNL63 N protein. Western blot analysis with truncated fragments of N protein suggested that its epitope resides in AA381-419 at the C-termin

Specificty of the original mouse IgG1 version of this antibody to SARS-CoV-2 and SARS-Cov was confirmed by Specificty of the original mouse IgG1 version of this antibody to SARS-CoV-2 and SARS-Cov was confirmed by ELISA (Terry et al., 2021; pmid: 33714753). This antibody detected SARS-Cov-2 N protein in Western blot exhibiting labeling patterns suggesting a linear epitope (Terry et al., 2021; pmid: 33714753). mBG17 was shown to be very effective in staining SARS-Cov-2 N protein in immunofluorescence in SARS-Cov-2-infected Vero cells, both methanol and paraformaldehyde fixed (Terry et al., 2021; pmid: 33714753). Finally, the original version of mBG17 was demonstrated to be an effective detection antibody in a sandwich ELISA assay suggesting its potential use in SARS-Cov-2 diagnostics (Terry et al., 2021; pmid: 33714753).

ImmunoFluorescence, Western Blot, ELISA

Research Use Only

Monoclonal

mBG17

N

nucleocapsid phosphoprotein

GU280_gp10; nucleocapsid phosphoprotein

Human

IgG1

Nucleoprotein

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Virus

-20°C,2°C to 8°C

12352203